193 related articles for article (PubMed ID: 24196790)
21. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.
Advani SJ; Markert JM; Sood RF; Samuel S; Gillespie GY; Shao MY; Roizman B; Weichselbaum RR
Gene Ther; 2011 Nov; 18(11):1098-102. PubMed ID: 21544094
[TBL] [Abstract][Full Text] [Related]
22. Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome.
Glass M; Söling A; Messerle M
J Neurovirol; 2008 Nov; 14(6):522-35. PubMed ID: 18979278
[TBL] [Abstract][Full Text] [Related]
23. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
Fu X; Rivera A; Tao L; Zhang X
Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic HSV-Infected Glioma Cells Activate NOTCH in Adjacent Tumor Cells Sensitizing Tumors to Gamma Secretase Inhibition.
Otani Y; Yoo JY; Chao S; Liu J; Jaime-Ramirez AC; Lee TJ; Hurwitz B; Yan Y; Dai H; Glorioso JC; Caligiuri MA; Yu J; Kaur B
Clin Cancer Res; 2020 May; 26(10):2381-2392. PubMed ID: 32139403
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.
Aghi M; Visted T; Depinho RA; Chiocca EA
Oncogene; 2008 Jul; 27(30):4249-54. PubMed ID: 18345032
[TBL] [Abstract][Full Text] [Related]
27. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
28. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
29. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
31. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
[TBL] [Abstract][Full Text] [Related]
32. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
Ino Y; Saeki Y; Fukuhara H; Todo T
Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
34. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
[TBL] [Abstract][Full Text] [Related]
35. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
36. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.
Zhang J; Chen H; Chen C; Liu H; He Y; Zhao J; Yang P; Mao Q; Xia H
Cancer Lett; 2021 Jul; 509():26-38. PubMed ID: 33819529
[TBL] [Abstract][Full Text] [Related]
37. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
38. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
Kahramanian A; Kuroda T; Wakimoto H
Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
Yoo JY; Swanner J; Otani Y; Nair M; Park F; Banasavadi-Siddegowda Y; Liu J; Jaime-Ramirez AC; Hong B; Geng F; Guo D; Bystry D; Phelphs M; Quadri H; Lee TJ; Kaur B
Neuro Oncol; 2019 Sep; 21(9):1131-1140. PubMed ID: 31063549
[TBL] [Abstract][Full Text] [Related]
40. A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.
Takaoka H; Takahashi G; Ogawa F; Imai T; Iwai S; Yura Y
Virol J; 2011 Jun; 8():294. PubMed ID: 21663640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
